Qiagen N.V.

Equities

QGEN

NL0015001WM6

Biotechnology & Medical Research

Market Closed - Nyse Other stock markets 04:00:02 2024-07-12 pm EDT			5-day change	1st Jan Change
42.18 ^USD	+2.60%		+2.63%	-5.79%

Jul. 09	AlphaValue/Baader Europe Upgrades Qiagen to Buy from Add, Lifts PT	MT
Jul. 08	Qiagen to Enhance the Identification of Human Remains of Indigenous People and African Americans	CI

QIAGEN N.V. Provides Earnings Guidance for the Fourth Quarter of 2020 and Full Year of 2021

January 12, 2021 at 09:10 am EST

QIAGEN N.V. provided earnings guidance for the fourth quarter of 2020 and full year of 2021. For the quarter, The company expects 32% CER growth sales. EPS between $0.54 to $0.65. For the full year 2021, The company expects EPS to $2.42 to $2.46. Targeting 18% to 20% sales growth.

Latest news about Qiagen N.V.

AlphaValue/Baader Europe Upgrades Qiagen to Buy from Add, Lifts PT	Jul. 09	MT
Qiagen to Enhance the Identification of Human Remains of Indigenous People and African Americans	Jul. 08	CI
Wolfe Research Upgrades Qiagen to Outperform From Peer Perform, Price Target is $50	Jun. 27	MT
Qiagen Seeks M&A	Jun. 21	CI
Transcript : Qiagen N.V. - Shareholder/Analyst Call	Jun. 21
Sartorius on the downswing again - low since 2020 is approaching	Jun. 19	DP
Invest Securities Raises Qiagen PT, Maintains Neutral Rating	Jun. 19	MT
UBS Raises Qiagen Price Target to $46 From $44, Maintains Neutral Rating	Jun. 18	MT
JPMorgan Raises Price Target on Qiagen to $54 From $52, Maintains Overweight Rating	Jun. 18	MT
QIAGEN NV : Gets a Neutral rating from UBS	Jun. 18	ZD
QIAGEN NV : Deutsche Bank reaffirms its Buy rating	Jun. 18	ZD
QIAGEN NV : Berenberg remains its Buy rating	Jun. 18	ZD
Frankfurt shares close: Dax recovers	Jun. 17	DP
Transcript : Qiagen N.V. - Analyst/Investor Day	Jun. 17
Dpa-AFX Overview: COMPANIES from 17.06.2024 - 15:15	Jun. 17	DP
Qiagen Targets 7% Annual Sales Growth Through 2028	Jun. 17	MT
Qiagen eyes sales growth of 7% per year until 2028	Jun. 17	RE
QIAGEN Announces the Release of A New Version of Its Clinical Decision Support Software, QCI Interpret	Jun. 13	CI
Qiagen Scraps NeuMoDx 96, 288 Molecular Systems; Raises 2024 Adjusted Earnings Outlook	Jun. 06	MT
Qiagen to Discontinue NeuMoDx Integrated PCR Testing System	Jun. 06	CI
Qiagen N.V. Reaffirms Earnings Guidance for the Second Quarter of 2024	Jun. 06	CI
Qiagen N.V. Launches Digital PCR Assay Design Tool for QIAcuity, Expands Customization Capabilities of Its Research Platform GeneGlobe	Jun. 05	CI
Qiagen Expands Qiastat-Dx Syndromic Testing Menu in the U.S. with Launch of Molecular Test to Improve Gastrointestinal Care	Jun. 03	CI
Qiagen, Myriad Genetics Team Up to Develop Homologous Recombination Deficiency Test	May. 31	MT
Qiagen, Myriad Genetics Partner to Create Easily Distributable Cancer Tumor Test	May. 31	MT

Chart Qiagen N.V.

Duration

Period

More charts

Company Profile

Qiagen NV is a holding company based in the Netherlands. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The Company's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.

Sector

Biotechnology & Medical Research

Calendar

2024-07-31 - Q2 2024 Earnings Release

Related indices

STOXX EUROPE 600 (EUR) , DAX

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

QIAGEN : A decent start to 2024; guidance unchanged

April 30, 2024 at 09:32 am EDT

More Strategies

Ratings for Qiagen N.V.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

42.18 USD

Average target price

49.73 USD

Spread / Average Target

+17.90%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
QIAGEN N.V.	-5.79%	9.36B
MODERNA, INC.	+22.10%	46.55B
LONZA GROUP AG	+46.45%	41.84B
IQVIA HOLDINGS INC.	-3.12%	40.84B
ALNYLAM PHARMACEUTICALS, INC.	+36.10%	32.95B
CELLTRION, INC.	-6.30%	28.27B
ICON PUBLIC LIMITED COMPANY	+18.71%	27.78B
UNITED THERAPEUTICS CORPORATION	+46.15%	14.26B
MEDPACE HOLDINGS, INC.	+44.52%	13.69B
BIO-TECHNE CORPORATION	+0.19%	12.18B

Other Biotechnology & Medical Research